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The Charles R. Ream, M D, Award for 
Excellence 2005 
The editorial board of Current Therapeutic Research is pleased to announce the 
recipient of the Charles R. Ream, MD, Award for Excellence--2005. "Effects of 
Pentosan Polysulfate in Osteoarthrit is of the Knee: A Randomized, Double- 
Blind, Placebo-Controlled Pilot Study," by Ghosh et al, 1 has been selected based 
on Dr. Ream's commitment to high-quality randomized control led studies with 
a direct and relevant scientific impact. The article by Ghosh et al demonstrated 
that even relatively small pilot studies can be implemented according to solid 
principles of clinical trial design. 
Osteoarthr i t is  i a chronic, debil itating disease that often leads to signifi- 
cant disability. Knee osteoarthr i t is  (KOA) might affect up to 10% of individ- 
uals aged >55 years and cause severe disabil ity in one quarter  of these 
patients. 2 Current pharmacologic  therapies for KOA aim to reduce radio- 
graphic joint-space narrowing and manage pain and functional imitations. 
NSAIDs are an important  component  of managing pain related to KOA but are 
associated with a significant risk for toxicity. Other therapies with proven 
effectiveness include intra-articular steroid injections and colchicine. Intra- 
articular hyaluronans have also shown a statistically significant clinical bene- 
fit, although invest igators have quest ioned the clinical importance of the 
small effect size seen. 3 
The aim of the 2005 Ream Award-winning article was to assess the utility of 
IM pentosan polysulfate (PPS) in managing KOA. To date, there have been sev- 
eral trials of PPS for the treatment of conditions ranging from chronic pelvic 
pain and interstitial cystitis to variant Creutzfeldt-Jakob disease. 4-6 Ghosh et al 7 
previously conducted an equine study, the results of which suggested beneficial 
effects of PPS on synovial fluid and articular cartilage. Their 2005 study was 
conducted to determine whether those findings could be replicated in humans 
with KOA. 
Although this small pilot s tudy was not designed to assess eff icacy or tol- 
erability, it was well designed and clearly presented.  The conclus ions were 
carefully worded and the data were accurate ly  presented.  The authors  de- 
fined a priori the clinically important improvement used to define effective- 
ness based on outcomes relevant o individual pat ients (ie, improved pain 
and functional disability). The sample size was calculated based on this in- 
formation to ensure that the study was powered to detect  clinically impor- 
tant outcomes.  
Clearly, further studies and assessments are needed to draw conclusions 
regarding the efficacy or tolerabil ity of PPS for the treatment of KOA. However, 
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although the study by Ghosh et at 1 was limited by a small sample size and the 
use of subjective outcomes variables, its design and presentation culminated in 
its receiving the sixth Charles R. Ream, MD, Award for Excellence. 
Judd L. Watson, MD, MPH 
Editor-m-Chief 
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